Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$7.08 USD
-0.06 (-0.84%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $7.07 -0.01 (-0.14%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Aurinia Pharmaceuticals Inc [AUPH]
Reports for Purchase
Showing records 1 - 20 ( 140 total )
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
2Q Recap: LUPKYNIS Guidance Range Narrowed; Advancing AUR200 Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
1Q24 Recap: Upward LUPKYNIS Trajectory Appears to be Gathering Momentum; Cashflow-Positive Beginning in 2Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Aurinia to Repurchase Up to 15% of Shares Under Exemptive Relief; Repurchases Began on February 21; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Lack of Acquirer Reflects Difficulty in Building LN Market
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
New Drug Prices for the New Year; We Highlight Three Recent Price Changes in Our Coverage Universe
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Optimized Entry and Exit Levels for AUPH 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Dr. Robert Foster Joins Aurinia''s Board As Part of Cooperation Agreement Between Aurinia and MKT Capital; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
2Q23 Recap: Second Beat-and-Raise Quarter in a Row; Raise PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Aurinia Continues to Expand Commercial Opportunities Globally With Swissmedic Approval of LUPKYNIS; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
4Q-2022 Results-Financial In Line; Most Forward Predictors Improving
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
4Q Recap: Encouraging Signs From Revitalized Commercial Execution Efforts; 2023 LUPKYNIS Sales Guidance Maintained
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E